Kaplan–Meier analysis confirmed that greater reductions in SMA significantly increased the risk of mortality (HR 5.1, 95% CI: 1.05–24.79; p = 0.025) and showed a trend toward higher risk of disease progression (HR 2.58, 95% CI: 0.89–7.49; p = 0.063).
Among these groups, SUV mean showed a trend of increasing values (G1, SUVmean = 5.04 ± 0.7; G2, SUV mean = 6.65 ± 0.91; G3, SUV mean = 7.04 ± 1.07; P = 0.063).
Hepatic cholesteryl esters, on the other hand, were significantly reduced in the combination treatment group compared to untreated control mice (−22%) and showed a trend towards a significant reduction compared to mice treated with ezetimibe alone (−13%, P = 0.063) ( Fig. 3 D).
Notably, AKI scores showed a trend toward a significant reduction in the subgroup ( P = 0.063).
Regarding the HbA1c levels, %IRF change showed a trend ( p = 0.063).
This was partly confirmed in the PS-adjusted Cox persistence analysis that showed a trend (p=0.0632) towards an interaction between the factor skin involvement and the treatment cohort, with longer persistence on ustekinumab in patients with baseline BSA >10% (HR: 0.41; 95% CI 0.19; 0.89).
Female treated mice also showed a trend toward decreased dermatan sulfate levels (p = 0.0635).
The manually segmented method showed lower microglia counts in the AD retina (manual control: 242.4 ± 24.50 count/mm 2 (mean ± SEM); manual AD: 165.0 ± 3.633 count/mm 2 (mean ± SEM); p = 0.0095), whereas the machine learning segmented method showed a trend of decreased microglia count per mm 3 (machine control: 12,213 ± 1378 count/mm 3 (mean ± SEM); machine AD: 8441 ± 799.6 count/mm 3 (mean ± SEM); p = 0.0635).
YOH mice (n = 5) showed a trend towards faster diagonally cross-matched ambulation than SAL controls (n = 4) with p = 0.0635 and AUC = 0.9 [0.6 1] (very strong effect), while ATI mice (n = 6) were faster than SAL (p = 0.0159, AUC = 1, very strong effect) and YOH mice (p = 0.0080, AUC = 1; very strong effect; Fig 2 ).
This was further supported by the survival report from the TCGA dataset in which patients harboring prostate cancer with TNC alteration showed a trend of decrease in disease-free survival ( P = 0.0637), although with no difference in the overall survival that may be affected by comorbidity (Figure 3 ).
Actinomycetota and Bacteroidota did not display significant differences in either relative or absolute abundance, though Bacteroidota showed a trend toward higher abundance in infants in the absolute analysis ( P = 0.0637).
For serum IgG responses, the targeted strain G5 [NC8(pYL595)] induced slightly higher antibody titers than the non-targeted strain G4 [NC8(pYL594)] against NetB (6.1% increase, P = 0.9858) and showed a trend toward higher titers against FBA (32.4% increase, P = 0.0638).
A172 cells showed a trend for increased migration to 0.5% FBS; p = 0.0638.
Moreover, Mindin immunostaining showed a trend of positive correlation with foot process effacement (p < 0.0639, rS = 0.3213, Fig 3A ), which was significant for the class III DN group alone (p < 0.0349, rS = 0.4417, Fig 3B ).
Eyes with pachydrusen in Category 2 showed a trend to have larger SFCT compared to those without pachydrusen ( P = 0.0639), but such a trend was absent in Category 3 ( Fig 5 ).
Density showed a trend level of a negative cluster ( p = .0639) ( Fig. 2 B).
Holm-Bonferroni tests revealed that Hcrtr1 antagonism significantly reduced DAT sensitivity to cocaine at the 30 μM cocaine concentration ( p < 0.0293), showed a trend for reduced effects at the 10 μM concentration ( p < 0.0639), but did not affect DAT sensitivity at other concentrations (0.3 μM, p < 0.2966; 1 μM, p < 0.1953; 3 μM, p < 0.2350).
NS-398 showed a trend to reduce inflammation in TNBS colitis rats ( p = 0.064 vs.
Compared with patients with PNI ≥48.9, those with PNI <48.9 showed a trend toward lower BMI (26.3 ± 3.2 vs 26.9 ± 3.5, P = .064), higher prevalence of chronic obstructive pulmonary disease (8.7% vs 4.9%, P = .091), a greater proportion of higher American Society of Anesthesiologists grade (III or above: 15.8% vs 9.9%), less intraoperative blood loss (112.5 ± 35.4 vs 126.5 ± 63.7 ml), and significantly lower platelet and red blood cell counts, hematocrit, hemoglobin (P, total cholesterol, triglycerides, and creatinine, as well as higher hs-CRP concentrations.
control, p < 0.05), while O+B showed a trend of increased global H3K4me2 compared to the olanzapine-only group ( p = 0.064) ( Figure 4 A).
Carriers of the ABI3 _rs616338-T variant showed a trend for greater NFT burden in PSP (ß = 0.38, 95% CI − 0.022 to 0.786, p = 0.064) (Table 4 ) but there were no associations or trends for CB, TA, TAUTH, or Overall tau burden for this variant.
These beliefs did not differ significantly, but showed a trend in this direction Z = − 1.867, p = 0.064, r = 0.09.
2 ), while sex showed a trend toward a positive correlation ( r = 0.256, p = 0.064) (Table 1 ).
30.0 °C, P = 0.004), while Ho:YAG showed a trend toward higher temperatures in dusting mode (40.6 °C vs. 35.8 °C, P = 0.064).
Pairwise comparison showed a trend toward lower GWI in HCM vs HC ( P = 0.064) but no significant difference between FH and HC ( P = 0.235).